TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naive, genotype 1 only, compensated, chronic hepatitis C infected Caucasian or African-American patients~* Body weight greater than 61 kg and not more than 87.3 kg~* HCV RNA greater than 2 million copies/mL~* Elevated measured or historical alanine aminotransferase~* Hemoglobin at least 12.0 g/dL for females and at least 13.0 g/dL for males~* Calculated creatinine clearance greater than 70 mL/min~Exclusion Criteria:~* Cirrhosis of the liver~* Alanine aminotransferase greater than 3 times the upper limit of normal~* Severe neuropsychiatric disorders~* History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic, or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune mediated disease~* Other co-morbid chronic viral infections including hepatitis B and the human immunodeficiency virus (HIV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient greater than or equal to 18 years of age with diagnosis of RA (Rheumatoid Arthritis) and no history of chronic arthritis before age 16.~2. Patient meets the requirements for treatment with adalimumab per the local product label.~3. Patient is naïve to adalimumab, and has not used any other immunomodulatory biologic\* DMARD (Disease Modifying Antirheumatic Drugs) in the past 8 weeks before the Baseline visit (\*rituximab may not have been used in the past 104 weeks before the Baseline visit).~4. Patient must be able and willing to provide written authorization (or informed consent where applicable) to disclose and use personal health information and comply with the requirements of this study protocol as well as agree to data being collected by Abbott.~Exclusion Criteria:~1. Patient is currently being treated with or has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or five half lives (whichever is longer) of the drug prior to the Baseline visit.~2. Prior clinically active TB (tuberculosis): if patient has had prior clinically active TB, there should be documentation that a full course of appropriate anti-TB therapy was completed or an ongoing full course of appropriate anti-TB therapy has been started before initiation of adalimumab in accordance with the local product label; otherwise, the patient will not be eligible to participate in this study.~3. Patient who intends to take less than 6 consecutive (every other week) injections of adalimumab.~4. Patients should not be enrolled if they cannot be treated with adalimumab in accordance with the local product label or if the Investigator determines that they should not be enrolled based on his/her clinical judgment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: None): Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Opioids on Heart Rate During Rapid Sequence Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient over 65 years old and any possible ASA OR Patient aged 55 to 65 years old with an ASA ≥ 3,~* Patient undergoing surgery (urgent or scheduled), requiring general anesthesia in rapid sequence, because considered to have a full stomach, i.e. with: gastro-oesophageal pathology or gastroparesis or a history of bariatric surgery or food intake within two hours for liquids and within six hours for solids,~* Patient informed of the study who gave their written consent before starting the study procedures,~* Patient affiliated to a French social security system.~Exclusion Criteria:~* Patient \< 55 years old,~* Patient on beta blockers,~* Atrial fibrillation or other rhythm or conduction disturbances,~* Patient in hemodynamic failure and/or on catecholamines before the start of GA,~* Patient having a history of stroke, hemorrhagic and/or ischemic and/or transient~* Combination with opioid agonists-antagonists or partial opioid antagonists~* Known hypersensitivity to one of the study drugs or to opioids,~* History of difficult intubation,~* Patient under guardianship, curatorship or deprived of liberty,~* Patient participating in another interventional clinical research,~* Patient under AME (State Medical Aid)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (placebo + remifentanil) (Type: EXPERIMENTAL): None
- Group B (sufentanil + placebo) (Type: EXPERIMENTAL): None
- Group C (placebo + placebo) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Direct Laryngoscopy, Truview EVO2 and Glidescope in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-III~* elective general surgical procedures~* from 0-10 years-old~Exclusion Criteria:~* increase intracranial pressure~* history of severe gastrointestinal reflux~* sore throat~* upper respiratory airway infection~* known or suspected difficult airway or coagulopathy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Macintosh blade (Type: ACTIVE_COMPARATOR): Intubation with Macintosh blade laryngoscope
- Glidescope (Type: ACTIVE_COMPARATOR): Intubation with Glidescope laryngoscope
- Truview PCD (Type: ACTIVE_COMPARATOR): Intubation with the Truview PCD laryngoscope

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Physical Rehabilitation Program Using the Nintendo Wii on Children With Osteogenesis Imperfecta (OI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Children affiliated to a social security scheme~* Children diagnosed OI by a competent physician of one of the French specialist centers;~* OI children type 1 or type 4;~* Stable OI (far from a fractional episode of at least two months);~* Children without regular activity on the Nintendo Wii console or other interactive console;~* Boy or Girl\> 6 to 18 years~* Parents or person having parental authority affiliated to a social security scheme~* Parents or person having parental authority who signed the consent form for the study.~Exclusion Criteria:~* - Children who can not walk;~* Children with severe OI other than type 1 or type 4;~* Fracture during the last two months;~* Surgical intervention within the last 8 months;~* Inability to understand and follow the protocol;~* Participation in another clinical study;~* Children, parents or holder of parental authority refusing the written consent.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- OI Children training with Nintendo Wii console (Type: EXPERIMENTAL): Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
- Children with OI without training (Type: NO_INTERVENTION): No training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Clinical Evaluation of Dozee VS, a Contactless Continuous Vital Parameters Monitoring System in Hospital Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adults Male or female. (Above 18 years of age)~2. Provide written informed consent.~3. Weight between 40kg/88.18lbs and 120kg/264.55lbs(Above 40 kgs)~4. Are located in a non-ICU hospital setting.~5. Agree to not eat during the testing period (2hours or 10 hours accordingly)~Exclusion Criteria:~1. Are connected to a device which may interfere with the device monitoring in this study.~2. Are receiving any bedside care which may be incompatible with the study procedures.~3. A likely need to receive or undergo a procedure during the testing period.~4. Cannot accept a nasal cannula, or have a monitor lead placed on the chest.~5. Have a significant medical condition in the judgement of the investigator, which may compromise the study testing procedures.~6. Prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm Study (Cohort) (Type: None): All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simulataneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Estrogen for Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically confirmed breast cancer which is metastatic.~* A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from either a prior biopsy of the primary tumor or a metastatic site. .~* Primary tumor or metastatic biopsy lacking estrogen and progesterone receptor and Her2 negative~* Patients must have measurable disease.~* Eastern Cooperative Oncology Group performance status 0-1.~* Patients with bone metastasis at baseline must agree to treatment with intravenous bisphosphonates~* Subjects may have had 0-4 lines of prior systemic chemotherapy or targeted therapy regimens administered for treatment of their metastatic breast cancer.~* Age \>18 years~* Life expectancy of greater than 3 months.~* Patients must have adequate organ and marrow function as defined below:~Exclusion Criteria:~* systemic chemotherapies, targeted therapies or radiotherapy for their cancer within 2 weeks prior to entering the study~* Patients receiving any other investigational agents for breast cancer treatment.~* Patients with known brain metastases are excluded 3.2.4 History of allergic reactions attributed to compounds of similar chemical or biologic composition to estradiol.~* Patients with any condition of the gastrointestinal tract that is expected to result in an inability to take oral medication~* Dysfunctional or post-menopausal vaginal bleeding.~* Uncontrolled hypercalcemia/hypocalcemia~* Prior history of or active thrombophlebitis, cerebral vascular accident, myocardial infarction, deep venous thrombosis or pulmonary embolism.~* History of or active hepatic adenoma.~* Uncontrolled intercurrent illness~* Pregnant women are excluded from this study~* Patients with bone metastasis are excluded if they are unable to receive intravenous bisphosphonate therapy due to the risk for developing hypercalcemia.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estrogen Therapy (Type: EXPERIMENTAL): Estrogen therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Immobilization Without Reduction vs. Reduction Under General Anesthesia in Metaphyseal Fractures of the Distal Radius

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children from 5 years to 10 years~* Unilateral metaphyseal distal radius fracture~* Fracture shortening of 0 to 10mm or angulation of 10 ° to 20 ° in the oblique plane. (AO 23-M 2-3 or 23r-M 2-3)~* Admission in the first 14 days after the fracture~Exclusion Criteria:~* Polytrauma: Injury Severity Score (ISS)\> 16~* Associated fracture in the same limb.~* Neuromuscular pathology (e.g., cerebral palsy, spinal muscular atrophy, Duchenne disease)~* Open fractures.~* History of fractures, septic arthritis, or osteomyelitis in the same limb.~* Neurological or vascular injury in the fractured upper limb.~* Known alteration of bone metabolism (e.g., osteogenesis imperfecta, rickets, osteopetrosis, skeletal dysplasias, lysosomal storage diseases).~* Congenital longitudinal deficiency.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- In situ immobilization (Type: EXPERIMENTAL): Immobilization without reducing the radius fracture and above-elbow casting.
- Reduction under general anesthesia (Type: ACTIVE_COMPARATOR): Radius closed reduction under general anesthesia and above-elbow casting. Percutaneous fixation with K-wires, a sugar tong splint immobilization, and a nerve block if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Furosemide in Early Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed and written consent by patient or surrogate~* Peripheral or central intravenous catheter~* The presence of early AKI~* 2 or more criteria for the systemic inflammatory response syndrome (SIRS) within 24 hours~* Achieved immediate resuscitation goals~Exclusion Criteria:~* Confirmed or suspected pregnancy~* Age \<18 years~* Stage 4 or greater chronic kidney disease or kidney transplantation~* Acute pulmonary edema requiring urgent use of furosemide or RRT~* Patient is moribund with expected death within 24 hours~* Known or suspected drug allergy to furosemide~* Enrolled in concomitant randomized trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Furosemide (Type: ACTIVE_COMPARATOR): Furosemide intravenous continuous infusion
- Normal Saline (Type: PLACEBO_COMPARATOR): Normal saline titrated continuous intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging Evaluation of the Tissular Oxygen Saturation in Brain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Volunteers or Patients with cerebral lesion~Exclusion Criteria:~* claustrophobia~* MRI exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patient (Type: OTHER): Imaging
- healthy subject (Type: OTHER): Imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* the patients with pathologically proved NASH (non-alcoholic steato-hepatitis)~Exclusion Criteria:~* alcohol consumption \> 20g/day~* viral hepatitis B and C~* autoimmune hepatitis~* Wilson's disease~* hemochromatosis~* alpha-1 antitrypsin deficiency~* breast-feeding or pregnant females~* subjects planning to become pregnant~* severe comorbid medical conditions (such as severe cardiac, pulmonary, renal or psychological problems)~* those not consenting for the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): None
- Rosiglitazone (Type: EXPERIMENTAL): Rosiglitazone (8 mg/day)
- alpha-lipoic acid (Type: EXPERIMENTAL): alpha-lipoic acid (1800 mg/day)
- Rosiglitazone/alpha-lipoic acid (Type: EXPERIMENTAL): combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male patient~* Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases~* No visceral metastases~* Decision to initiate treatment with Radium-223 was made independently prior to patient enrollment in the study as per investigator's routine treatment practice~* Signed informed consent~Exclusion Criteria:~* Patients previously treated with Radium-223 for any reason~* Patients currently treated in any other clinical trials including other Radium-223 studies~* Patients are planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use~* Participation in an investigational program with interventions outside of routine clinical practice~* Patients previously treated with Docetaxel~* Patients under treatment with Abiraterone Acetate and the Corticosteroids Prednisone or Prednisolone~Besides Inclusion and exclusion criteria, sites should also follow the locally approved Radium-223 product information

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride treatment (Type: None): Castration-resistant prostate cancer (CRPC) patients with bone metastases for whom a decision has been made independently by the treating physician and the patient to treat with Radium-223.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lutein and Alzheimer's Disease Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with moderately severe Alzheimer's disease

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Daily Lutein/zeaxanthin supplementation with a meal
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues